- Home
- AEXA vs KALV Comparison
AEXA vs KALV Comparison
Compare AEXA & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEXA | KALV |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.5M | 551.2M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | AEXA | KALV |
|---|---|---|
| Price | $11.24 | $15.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 262.9K | ★ 863.2K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.49 | $8.96 |
| 52 Week High | $11.91 | $19.00 |
Technical Indicators
Market Signals| Indicator | AEXA | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 49.00 |
| Support Level | $11.25 | $14.41 |
| Resistance Level | $11.80 | $16.59 |
| Average True Range (ATR) | 0.25 | 0.86 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 2.63 | 40.22 |
Price Performance
Historical ComparisonAbout AEXA American Exceptionalism Acquisition Corp. A
American Exceptionalism Acquisition Corp A is a blank check company.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.